STVN
Stevanato Group
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About STVN
Stevanato Group S.P.A.
The first worldwide producer of insulin cartridges for diabetes treatment
Life Science Tools and Services
Invalid Date
07/16/2021
New York Stock Exchange
5521
12-31
Common stock
Via Molinella 17, 35017 Piombino Dese – Padua, Italy
--
Stevanato Group S.p.A. is incorporated under the laws of the Republic of Italy. The company is a leading global provider of drug containment, drug delivery and diagnostic solutions and engineering solutions for the pharmaceutical, biotechnology and life science industries. The company offers an integrated, end-to-end portfolio of products, processes and services that meet customer needs throughout the drug lifecycle, from development to the clinical and commercial stages.
Company Financials
EPS
STVN has released its 2024 Q2 earnings. EPS was reported at 0.10, versus the expected 0.11, missing expectations. The chart below visualizes how STVN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
STVN has released its 2024 Q4 earnings report, with revenue of 342.20M, reflecting a YoY change of -3.52%, and net profit of 50.01M, showing a YoY change of -0.06%. The Sankey diagram below clearly presents STVN’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
